Franklin Templeton, managing $1.8 trillion in assets, filed with the SEC to launch two ETFs that combine U.S. stock exposure with Bitcoin investment. The Franklin US Equity Bitcoin DRIP Index ETF and Franklin US Innovation Bitcoin DRIP Index ETF use dividends from stocks to buy Bitcoin, starting with 95% stocks and 5% Bitcoin, capped at 20% Bitcoin exposure. These ETFs aim to gradually increase Bitcoin holdings through dividend reinvestment plans, offering a hybrid investment approach. The ETFs target large-cap and Nasdaq growth stocks, with fees of 0.09% and 0.19%, respectively, and may gain Bitcoin exposure via various financial instruments. The SEC filing is effective October 27, 2026, pending final approvals.
Franklin Templeton manages $1.8 trillion in assets and has filed for two ETFs linking U.S. stocks and Bitcoin. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 26, 2026 17:21 WIB: out of 50 major cryptocurrencies, 26 rose and 22 fell. Notable movers include COMP at Rp376.628 with a 1-day change of -9.90% and a typical hold time of 98 days, EOS at Rp12.649 up 8.13%, and BAT at Rp2.647 down 5.44%.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
